BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin

Aug 23, 2022

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake,” reads a recent article. “CNS Pharmaceuticals is conducting a potentially pivotal global phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a standard-of-care chemotherapy agent used in the treatment of GBM patients as the tumor progresses. Patients are being enrolled at 19 sites thus far, with 42 more anticipated across the United States, Italy, France, Spain and Switzerland now that European regulatory approvals have been granted. The U.S. Food and Drug Administration (‘FDA’) has granted ‘fast-track’ and ‘orphan drug’ status to Berubicin, demonstrating the value of CNS’s initial successes in opening regulatory pathways for the drug’s market priority if it can continue to show success in its trial stage.”

To view the full article, visit https://ibn.fm/Ol5V7

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

More News

MP criticises Guernsey and Jersey company ownership register plans
Nov 22, 2026
MP criticises Guernsey and Jersey company ownership register plans

Sir Andrew Mitchell says access should be easier for people tackling financial crime.

Italian jeweller and businessman Paolo Bulgari dies aged 89
Nov 22, 2026
Italian jeweller and businessman Paolo Bulgari dies aged 89

In a statement to Italian media, his family remember him as "the greatest jeweller of our time".

Employers are being asked to give interview feedback - here's what applicants want
Nov 22, 2026
Employers are being asked to give interview feedback - here's what applicants want

People say they often hear nothing back after applying for jobs. But could employers be forced to respond to every applicant?

The Penny Is Dead. Now It’s Official.
Nov 21, 2026
The Penny Is Dead. Now It’s Official.

President Trump signed a law on Friday formally putting the penny out of mint, a year after it stopped being struck.

Nvidia Said to Face S.E.C. Probe Into Its Accounting Practices
Nov 21, 2026
Nvidia Said to Face S.E.C. Probe Into Its Accounting Practices

Questions around the company’s accounting had surfaced amid revelations about its questionable chip sales in Asia.

The Used Car Industry Is Booming. This N.J. Campus Is Setting the Price.
Nov 21, 2026
The Used Car Industry Is Booming. This N.J. Campus Is Setting the Price.

As new car prices rise beyond the means of most buyers, the used market has become much more important for consumers and the auto industry.

Many Etsy Sellers Close Up Shop Over Site’s New A.I. Policy
Nov 21, 2026
Many Etsy Sellers Close Up Shop Over Site’s New A.I. Policy

Numerous longtime users of the online marketplace have left the platform because they do not want their work training artificial intelligence. Etsy said it would revise its policy.

Maldon Salt’s Authenticity Is Questioned, Leaving Foodies Shaken
Nov 21, 2026
Maldon Salt’s Authenticity Is Questioned, Leaving Foodies Shaken

The salt is a flaky favorite of food influencers and famous chefs. A revelation this week raised questions about what makes artisanal “artisanal.”

Elon Musk on His Politics, a Potential Merger and Ukraine
Nov 21, 2026
Elon Musk on His Politics, a Potential Merger and Ukraine

The chief executive of Tesla and SpaceX spoke with Andrew Ross Sorkin at the DealBook Summit.

Turkey’s Van Cats Contend With Rising Temperatures
Nov 21, 2026
Turkey’s Van Cats Contend With Rising Temperatures

A feline research center in Turkey uses air-conditioning and pools to keep residents comfortable as their numbers recover. And yes, they like to swim.

Sessions offer advice on rising energy costs
Nov 21, 2026
Sessions offer advice on rising energy costs

A council is urging people to seek support with rising energy costs on heating this winter.

Why are global business leaders impressed by Shenzhen?
Nov 21, 2026
Why are global business leaders impressed by Shenzhen?

Why are global business leaders impressed by Shenzhen?

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Manage The Numbers

Manage The Numbers is the world’s fastest-growing finance news website, featuring the latest money and market news, along with in-depth analysis so you can make the best decision.

Newsletter